Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2017 | Original Article

JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin

Authors: Mingning Qiu, Longzhi Ke, Sai Zhang, Xin Zeng, Zesong Fang, Jianjun Liu

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2017

Abstract

Purpose

Doxorubicin, a highly effective and widely used anthracycline antibiotic in multiple chemotherapy regimens, has been limited by its cardiotoxicity. The aim of this study is to investigate the effect of nitric oxide donor prodrug JS-K on proliferation and apoptosis in renal carcinoma cells and cardiac myocytes toxicity induced by Doxorubicin and to explore possible p53-related mechanism in renal carcinoma cells.

Methods

The effect of JS-K on anti-cancer activity of Doxorubicin was investigated in renal carcinoma cells via detecting cell proliferation, cytotoxicity, cell death and apoptosis and expressions of apoptotic-related proteins. Effect of p53 on the combination of JS-K and Doxorubicin was determined using p53 inhibitor Pifithrin-α and p53 activator III. Furthermore, the effect of JS-K on cardiac myocytes toxicity of Doxorubicin was investigated in H9c2 (2-1) cardiac myocytes via measuring cell growth, cell death and apoptosis, expressions of proteins involved in apoptosis and intracellular reactive oxygen species.

Results

We demonstrated that JS-K could increase Doxorubicin-induced renal carcinoma cell growth suppression and apoptosis and could increase expressions of proteins that are involved in apoptosis. Additionally, Pifithrin-α reversed the promoting effect of JS-K on Doxorubicin-induced renal carcinoma cell apoptosis; conversely, the p53 activator III exacerbated the promoting effect of JS-K on Doxorubicin-induced renal carcinoma cell apoptosis. Furthermore, JS-K protected H9c2 (2-1) cardiac myocytes against Doxorubicin-induced toxicity and decreased Doxorubicin-induced reactive oxygen species production.

Conclusions

JS-K enhances the anti-cancer activity of Doxorubicin in renal carcinoma cells by upregulating p53 expression and prevents cardiac myocytes toxicity of Doxorubicin by decreasing oxidative stress.

Smolensky D, Rathore K, Cekanova M (2015) Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of Doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro. BMC Cancer 15:927. doi:10.1186/s12885-015-1930-5 CrossRefPubMedPubMedCentral

Zhu H, Luo P, Fu Y, Wang J, Dai J, Shao J, Yang X, Chang L, Weng Q, Yang B, He Q (2015) Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin. Oncotarget 6(5):3254–3267. doi:10.18632/oncotarget.2410 CrossRefPubMed

Becker PS, Gooley TA, Green DJ, Burwick N, Kim TY, Kojouri K, Inoue Y, Moore DJ, Nelli E, Dennie T, Bensinger WI (2016) A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal Doxorubicin and dexamethasone for newly diagnosed multiple myeloma. Blood Cancer J 6:e422. doi:10.1038/bcj.2016.31 CrossRefPubMedPubMedCentral

Ahmadi F, Mojarrab M, Ghazi-Khansari M, Hosseinzadeh L (2015) A semipolar fraction of petroleum ether extract of Artemisia aucheri induces apoptosis and enhances the apoptotic response to Doxorubicin in human neuroblastoma SKNMC cell line. Res Pharm Sci 10(4):335–344PubMedPubMedCentral

Muggia FM, Speyer JL (1999) Doxorubicin-induced cardiomyopathy. N Engl J Med 340(8):654–655PubMed

Takemura G, Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49(5):330–352. doi:10.1016/j.pcad.2006.10.002 CrossRefPubMed

Mitry MA, Edwards JG (2016) Doxorubicin induced heart failure: phenotype and molecular mechanisms. Int J Cardiol Heart Vasc 10:17–24. doi:10.1016/j.ijcha.2015.11.004 PubMed

Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 279(24):25535–25543. doi:10.1074/jbc.M400944200 CrossRefPubMed

Hovorka O, Subr V, Vetvicka D, Kovar L, Strohalm J, Strohalm M, Benda A, Hof M, Ulbrich K, Rihova B (2010) Spectral analysis of Doxorubicin accumulation and the indirect quantification of its DNA intercalation. Eur J Pharm Biopharm 76(3):514–524. doi:10.1016/j.ejpb.2010.07.008 CrossRefPubMed

10.

Kim KH, Oudit GY, Backx PH (2008) Erythropoietin protects against Doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharm Exp Ther 324(1):160–169. doi:10.1124/jpet.107.125773 CrossRef

11.

Venkatesan B, Prabhu SD, Venkatachalam K, Mummidi S, Valente AJ, Clark RA, Delafontaine P, Chandrasekar B (2010) WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks Doxorubicin-induced cardiomyocyte death. Cell Signal 22(5):809–820. doi:10.1016/j.cellsig.2010.01.005 CrossRefPubMedPubMedCentral

12.

Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC (2007) JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110(2):709–718. doi:10.1182/blood-2006-10-052845 CrossRefPubMedPubMedCentral

13.

McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK, Tari AM (2011) JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int J Oncol 38(4):963–971. doi:10.3892/ijo.2011.925 PubMed

14.

Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, Schrader M, Cronauer MV (2012) JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells. BMC Cancer 12:130. doi:10.1186/1471-2407-12-130 CrossRefPubMedPubMedCentral

15.

Qiu M, Chen L, Tan G, Ke L, Zhang S, Chen H, Liu J (2015) A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells. Sci Rep 5:15104. doi:10.1038/srep15104 CrossRefPubMedPubMedCentral

16.

Liu L, Wang D, Wang J, Wang S (2016) The Nitric oxide prodrug JS-K induces Ca(2+)-mediated apoptosis in human hepatocellular carcinoma HepG2 Cells. J Biochem Mol Toxicol 30(4):192–199. doi:10.1002/jbt.21778 CrossRefPubMed

17.

Gunzle J, Osterberg N, Saavedra JE, Weyerbrock A (2016) Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme. Cell Death Dis 7(9):e2349. doi:10.1038/cddis.2016.254 CrossRefPubMedPubMedCentral

18.

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10(12):1321–1328. doi:10.1038/nm1146 CrossRefPubMed

19.

Theodoulou M, Hudis C (2004) Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional Doxorubicin? Cancer 100(10):2052–2063. doi:10.1002/cncr.20207 CrossRefPubMed

20.

Wang G, Zhang J, Liu L, Sharma S, Dong Q (2012) Quercetin potentiates Doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS ONE 7(12):e51764. doi:10.1371/journal.pone.0051764 CrossRefPubMedPubMedCentral

21.

Green DR (2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell 102(1):1–4CrossRefPubMed

22.

Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2):153–164CrossRefPubMed

23.

Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M (2009) Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Can Res 69(23):9056–9064. doi:10.1158/0008-5472.CAN-09-1770 CrossRef

24.

Liu T, Xiong J, Yi S, Zhang H, Zhou S, Gu L, Zhou M (2016) FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Oncogene. doi:10.1038/onc.2016.331

25.

Walia V, Kakar S, Elble R (2011) Micromanagement of the mitochondrial apoptotic pathway by p53. Front Biosci (Landmark Ed) 16:749–758CrossRef

26.

Chipuk JE, Green DR (2009) PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle 8(17):2692–2696. doi:10.4161/cc.8.17.9412 CrossRefPubMedPubMedCentral

27.

Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, Aydin A, Oktenli C, Koc B, Inal V, Yamanel L, Yaman H (2009) Effects of N-acetylcysteine, deferoxamine and selenium on Doxorubicin-induced hepatotoxicity. Biol Trace Elem Res 132(1–3):184–196. doi:10.1007/s12011-009-8377-y CrossRefPubMed

28.

Liu B, Tan X, Liang J, Wu S, Liu J, Zhang Q, Zhu R (2014) A reduction in reactive oxygen species contributes to dihydromyricetin-induced apoptosis in human hepatocellular carcinoma cells. Sci Rep 4:7041. doi:10.1038/srep07041 CrossRefPubMedPubMedCentral

29.

Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK (2011) The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. J Pharm Exp Ther 336(2):313–320. doi:10.1124/jpet.110.174904 CrossRef

30.

Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK (2003) JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2(4):409–417PubMed

31.

Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11(24 Pt 1):8782–8788. doi:10.1158/1078-0432.CCR-05-1664 CrossRefPubMed

32.

Peng ZH, Kopecek J (2015) Enhancing accumulation and penetration of HPMA copolymer-Doxorubicin conjugates in 2D and 3D prostate cancer cells via iRGD conjugation with an MMP-2 cleavable spacer. J Am Chem Soc 137(21):6726–6729. doi:10.1021/jacs.5b00922 CrossRefPubMedPubMedCentral

33.

Esparza-Lopez J, Ramos-Elias PA, Castro-Sanchez A, Rocha-Zavaleta L, Escobar-Arriaga E, Zentella-Dehesa A, Leon-Rodriguez E, Medina-Franco H, Ibarra-Sanchez Mde J (2016) Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases. BMC Cancer 16(1):740. doi:10.1186/s12885-016-2769-0 CrossRefPubMedPubMedCentral

Title: JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin
Authors: Mingning Qiu
Longzhi Ke
Sai Zhang
Xin Zeng
Zesong Fang
Jianjun Liu
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3359-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer

Eribulin shows high concentration and long retention in xenograft tumor tissues

A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)

Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer

Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

Keynote webinar | Spotlight on antibody–drug conjugates in cancer